Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Bispecific trivalent antibodies binding to Claudin6 or Claudin18.2 and CD3 for treatment of Claudin expressing cancer diseases

Bispecific trivalent antibodies binding to Claudin6 or Claudin18.2 and CD3 for treatment of Claudin expressing cancer diseases

US Patent 11787862 · Granted Oct 17, 2023

Estimated economic value: $86,471,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Method for reducing immunogenicity of RNA2025
Binding agents that bind OX40 (CD134) and method of use thereof to treat disease2025
Tumor antigens for determining cancer therapy2025
Antibodies capable of binding to OX40, variants thereof and uses thereof2025
Binding agents binding to EpCAM and CD1372025
Modification of RNA, producing an increased transcript stability and translation2025
Modification of RNA, producing an increased transcript stability and translation2025
Use of RNA for reprogramming somatic cells2025
Trans-replicating RNA2025
RNA replicon for reprogramming somatic cells2025
5′-cap-trinucleotide- or higher oligonucleotide compounds and their use in stabi2025
RNA replicon for versatile and efficient gene expression2025